Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer.
Aged
Biomarkers, Tumor
/ blood
Carcinoma, Non-Small-Cell Lung
/ blood
Female
Humans
Insulin-Like Growth Factor Binding Protein 3
/ blood
Insulin-Like Growth Factor I
/ genetics
Insulin-Like Growth Factor II
/ genetics
Male
Middle Aged
Neoplasm Staging
Pemetrexed
/ administration & dosage
Prognosis
Recombinant Proteins
Signal Transduction
/ drug effects
IGF-1
IGF-2
IGF-BP3
chemotherapy
non-small cell lung cancer
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
14
06
2019
revised:
27
06
2019
accepted:
28
06
2019
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
8
8
2019
Statut:
ppublish
Résumé
Insulin-like growth factor 1 (IGF-1)-mediated molecular pathway has been implicated in non-small cell lung cancer (NSCLC) pathogenesis and progression. We aimed to evaluate serum levels of IGF-1, IGF-2 and IGF-binding protein 3 (IGF-BP3) before and after standard treatment in patients with advanced NSCLC and their prognostic and predictive correlations. Seventy-three patients were prospectively included. Analysis and quantification of circulating levels of IGF1, IGF2, IGFBP3 were performed by total ELISA in peripheral blood samples at baseline and 3 months post-treatment. The median values of IGF-1 and IGF-1/IGF-BP3 ratios (125.82 vs. 133.4 ng/ml, p=0.087 and 0.01006 vs. 0.01252, p=0.011) were both decreased after treatment. Importantly, the post-treatment value of the ratio was significantly reduced only among responders to treatment (0.01044 from 0.01255, p=0.02). Reduction of IGF-1/IGF-BP3 ratio was statistically significant only among patients with NSCLC who responded to first-line treatment. If validated in larger cohorts, IGF-1/IGFBP3 might be a useful predictive tool for response to chemotherapy in NSCLC.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Insulin-like growth factor 1 (IGF-1)-mediated molecular pathway has been implicated in non-small cell lung cancer (NSCLC) pathogenesis and progression. We aimed to evaluate serum levels of IGF-1, IGF-2 and IGF-binding protein 3 (IGF-BP3) before and after standard treatment in patients with advanced NSCLC and their prognostic and predictive correlations.
PATIENTS AND METHODS
METHODS
Seventy-three patients were prospectively included. Analysis and quantification of circulating levels of IGF1, IGF2, IGFBP3 were performed by total ELISA in peripheral blood samples at baseline and 3 months post-treatment.
RESULTS
RESULTS
The median values of IGF-1 and IGF-1/IGF-BP3 ratios (125.82 vs. 133.4 ng/ml, p=0.087 and 0.01006 vs. 0.01252, p=0.011) were both decreased after treatment. Importantly, the post-treatment value of the ratio was significantly reduced only among responders to treatment (0.01044 from 0.01255, p=0.02).
CONCLUSION
CONCLUSIONS
Reduction of IGF-1/IGF-BP3 ratio was statistically significant only among patients with NSCLC who responded to first-line treatment. If validated in larger cohorts, IGF-1/IGFBP3 might be a useful predictive tool for response to chemotherapy in NSCLC.
Identifiants
pubmed: 31366504
pii: 39/8/4185
doi: 10.21873/anticanres.13578
doi:
Substances chimiques
Biomarkers, Tumor
0
IGF2 protein, human
0
Insulin-Like Growth Factor Binding Protein 3
0
Recombinant Proteins
0
Pemetrexed
04Q9AIZ7NO
Insulin-Like Growth Factor I
67763-96-6
Insulin-Like Growth Factor II
67763-97-7
mecasermin
7GR9I2683O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4185-4190Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.